Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

Bertrand Y. Tuan, MD, hematologist/oncologist at Pacific Hematology Oncology Associates and California Pacific Medical Center ...

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, ...

Sophie Cromer, an 8-year-old from Alabama, has faced a challenging journey after being diagnosed with aplastic anemia at the ...

China has completed a remote single-arm robotic surgery for a patient in the country Xizang Autonomous Region marking a major breakthrough in combini ...

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis ...

Sites in Los Angeles and near San Francisco California are enrolling people with severe SCD for a trial to test a gene ...

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments ...

Study finds annual healthcare costs per patient are significantly higher than previously described– HHT costs are higher than other ...

Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for ...

Munakka, also known as black raisins, is a powerhouse of nutrition that has been cherished in traditional medicine and ...

Crohn’s disease may be a lifelong condition, but today, there are an abundance of effective treatments that can help bring ...